Epigallocatechin-3-gallate (EGCG), a small molecule that been shown to inhibit the aggregation of several amyloidogenic proteins such as a-syn, amyloid-beta and huntingtin [9, 37, 38, 105] binds to unfolded native amyloid-beta and a-syn and promotes the formation of nontoxic oligomers that do not convert into amyloid fibrils [37].
In vitro studies have shown that curcumin inhibited the formation of fibrils and disaggregated amyloid-beta and a-syn [112, 114, 155].
furthermore, treatment with salubrinal, which alleviates ER stress, reduced oligomeric accumulation in the ER.
Not only did this discovery draw attention to aggregated forms of a-syn as mediators of Parkinson’s disease pathogenesis, but also opened the door to the use of a-syn detection techniques for diagnosis and staging.
In contrast, a-syn 30–110 that forms fibrils at a fast rate, did not display toxicity, indicating that oligomers are indeed the toxic species leading to TH-neuron loss in vivo [162].
a report by Hoffmann et al. showed that fibrillar a-syn induced a more pronounced inflammatory response in microglial cells [61].
. Multiple lines of evidence now suggest that oligomeric species of a-syn, which are thought to precede the fibrillar aggregates found in Lewy bodies, are the culprits for neuronal degeneration in Parkinson’s disease
Oligomeric detection may have uses as a diagnostic biomarker, as a biomarker of the progression of the disease, and in the future, perhaps as an index of response to novel therapies.
Elevated levels of a-syn oligomers were found in PD patients compared to controls or AD patients in brain homogenate, CSF and serum.
In vitro formed a-syn oligomers ectopically applied to cell cultures or formed due to overexpression of a-syn induce cell death [20, 30, 109, 149], which has been recapitulated in vivo in several studies.
In 2014 Plotegher et al. showed that mitochondrial morphology is disrupted by a-syn oligomers, which cause fragmentation of these organelles in vitro in SH-SY5Y cells [124].
All these results show that a-syn oligomers are implicated in mitochondrial dysfunction across different models.
Accumulation of oligomers has been demonstrated in a transgenic mouse overexpressing A53T a-syn and in Parkinson’s disease brain tissue, resulting in chronic ER stress and impaired ER protein quality control [25].
This can be inhibited by a-syn oligomers: oligomers were shown to inhibit proteasomal activity, which was blocked by addition of antibodies that neutralized the interaction [87].
However, in a different report, oligomers were shown to activate proinflammatory signals in microglial cells in vitro and in vivo, and this was prevented by addition of a MAP kinase inhibitor [161].
Kim et al. demonstrated that a-syn oligomers lead to microglial inflammatory responses via TLR2 activation [74].
Another report by Zhang and collaborators also highlighted glial activation and production of reactive oxygen species in response to oligomer-like preparations of aggregated a-syn [168].
A-syn oligomers can stabilize membrane defects accelerating membrane damage [19] and can alter membrane properties such as input resistance reducing neuronal excitability [72]
Dysfunctional membranes can also have an important impact on calcium homeostasis; some types of oligomers can lead to a cytotoxic calcium influx presumably by building pore-like structures [30].
The trafficking of synaptic vesicles may also be negatively impacted by a-syn oligomers, which have been shown to decrease axonal transport by decreasing microtubule stability and impairing the interaction between kinesin and microtubules [128], as well as inhibiting tubulin polymerisation [20].
Golgi fragmentation has also been observed as a result of oligomers formed by over-expression of a-syn in COS-7 cells [55].
Prabhudesai et al. showed that this molecule is able to inhibit the aggregation of a-syn in vitro and in a zebrafish model expressing human wild-type a-syn in neurons where CLR01 reduced apoptosis and improved embryo survival [127].
Interestingly, it was very recently reported that astrocytes take up a-syn oligomers and degrade it via the lysosomal pathway, but this pathway can become saturated leading to mitochondrial fragmentation [89].
a-syn accumulation has been linked to autophagic and lysosomal dysfunction, which may in turn lead to a-syn aggregation and production of more detrimental oligomers.
First, a-syn oligomers bind synaptobrevin, a component of the SNARE complex required for synaptic vesicle fusion, and prevent the formation of the SNARE complex [23].
Finally, inhibition of histone deacetylase 6 (HDAC6), which was previously shown to be involved in the response to cytotoxic ubiquitinated aggregates, increased the oligomeric content in vitro, while overexpression of HDAC6 produced the opposite effect [36].
Finally, Parkinson’s disease patients carrying familial mutations in the parkin gene, and some of those with the LRRK2 G2019S mutation, show neuronal degeneration in the absence of Lewy body formation [28, 50].
Over the past two decades, the pre-synaptic protein alphasynuclein (a-syn) has been irrefutably tied to the neurodegenerative disorder Parkinson’s disease.
the point mutation in SNCA (A53T) was demonstrated to cause autosomal dominant Parkinson’s disease [126] and several other point mutations (A30P, E46K, H50Q, G51D and A53E) have since been shown to cause familial forms of Parkinson’s disease and dementia with Lewy bodies (DLB) [4, 79, 84, 119, 129, 167].
Accordingly, overexpression of transcription factor EB (TFEB) was shown to correct lysosomal defects induced by the viral overexpression of a-syn and to downregulate the accumulation of oligomers in vivo [32].
USP19 promoted the secretion of a-syn, suggesting that MAPS is an unconventional secretion pathway utilized by a-syn, particularly under conditions of proteasomal impairment, which has been repeatedly linked to Parkinson’s disease.
BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.
If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.